BRAF and melanoma: Mutations in the Raf-MEK-ERK mitogen-activated protein kinase (MAPK) cell proliferation signalling pathway, including BRAF, NRAS and KIT mutations, are frequently detected in patients with malignant melanoma; the BRAF mutation rate in the Japanese population is about 30% [4].